Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation
- 8 March 2006
- journal article
- review article
- Published by Elsevier BV in European Journal of Pharmacology
- Vol. 533 (1-3), 101-109
- https://doi.org/10.1016/j.ejphar.2005.12.048
Abstract
No abstract availableKeywords
This publication has 63 references indexed in Scilit:
- Effect of rosiglitazone and 15-deoxy- 12,14-prostaglandin J2 on bleomycin-induced lung injuryEuropean Respiratory Journal, 2005
- 15-Deoxy-Δ12,14-prostaglandin J2inhibits IL-1β-induced IKK enzymatic activity and IκBα degradation in rat chondrocytes through a PPARγ-independent pathwayFEBS Letters, 2004
- Peroxisome Proliferator–activated Receptors α and γ Down-regulate Allergic Inflammation and Eosinophil ActivationThe Journal of Experimental Medicine, 2003
- PPAR‐α and ‐γ but not ‐δ agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF‐κB‐independent effectBritish Journal of Pharmacology, 2003
- Peroxisome proliferator–activated receptor γ agonists: Potential use for treating chronic inflammatory diseasesArthritis & Rheumatism, 2002
- 15-Deoxy-Δ12,14-prostaglandin J2 Inhibits IL-10 and IL-12 Production by MacrophagesBiochemical and Biophysical Research Communications, 2001
- Peroxisome proliferator‐activated receptor γ activators inhibit interleukin‐12 production in murine dendritic cellsFEBS Letters, 2000
- Peroxisome Proliferator-Activated Receptors: Nuclear Control of MetabolismEndocrine Reviews, 1999
- Signalling the fat controllerNature, 1996
- Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferatorsNature, 1990